Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Gold ETF (UGL) vs Viatris Inc (VTRS) Price & Performance

ProShares Ultra Gold ETFTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Gold ETF vs Viatris Inc — how do they compare? ProShares Ultra Gold ETF trades at $46.45 (market cap $716.59M), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 28× ProShares Ultra Gold ETF's market cap, and Viatris Inc pays a 2.75% dividend while ProShares Ultra Gold ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra Gold ETF for 23 Days and Viatris Inc for 57 Days on average.

UGLVTRS
Market Cap
$716.59M$20.03B
Volume
2,592,87814,109,977
Sector
Leveraged / InverseHealth
52-Week High
$85.62$18.27
52-Week Low
$42.79$9.74
Typical Hold Time
23 Days57 Days
Enterprise Value
—$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Gold ETF

UGL trades at $45.08, up 1.46% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Support is clustered around $44-$45, while resistance sits near $46. Recent news highlights gold's volatility amid shifting Fed rate expectations and Treasury yield pressures, impacting gold-related equities.

The outlook remains cautious due to weak technical momentum and macroeconomic headwinds like rising yields. Upside depends on sustained gold price recovery, but near-term risks from Fed policy and dollar strength suggest limited bullish catalysts. Investors should weigh the stock's sensitivity to commodity cycles against current bearish signals.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

UGL
100% Buy0% Sell
Avg holding period · 23 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About ProShares Ultra Gold ETF

UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.

Read more on UGL →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →